We announce our latest global expansion – the Asian market. As we take this leap, we are particularly thrilled to introduce our newest distributors, both led by ambitious female leaders!
EpiGuard is proud to announce that the EpiShuttle has secured a vital place in the 100% EU-funded Strategic CBRN Reserve!
EpiGuard’s single patient isolation transport unit is the only unit of its kind at the Westmead biocontainment centre!
EpiGuard is happy to announce our latest partnership with JS T&C, a prominent player in Korea’s healthcare landscape!
Working together towards enhancing preparedness in the Central European region, EpiGuard is thrilled to announce its strategic partnership with Glomex MS, a leading technology solutions provider.
EpiGuard has partnered with LRY Group – an esteemed global company dedicated to healthcare advancements.
The EpiShuttle was used in a simulation exercise organized by the Organization for the Prohibition of Chemical Weapons as a tool for strengthening national preparedness for CBRN events.
EpiShuttle’s first time in Japan! EpiGuard attended DSEI in Tokio and had a demonstration in Kyoto. Read more about it in the blog!
EpiGuard is proud to announce that the EpiShuttle has been approved by the Therapeutic Goods Administration (TGA) and is now available for use in the Australian market!
EpiGuard’s commitment to safety and quality was attested by our successful completion of an audit by the Norwegian Medicines Agency last June.
